These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Blockade of IL-6 signal exacerbates acute inflammatory bowel disease via inhibiting IL-17 producing in activated CD4+ Th17 population. Zhang SJ; Wang L; Ming L; Guo XB; Wang HM; Li XW; Li L Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3291-5. PubMed ID: 24379058 [TBL] [Abstract][Full Text] [Related]
29. Th17-related cytokines in inflammatory bowel diseases: friends or foes? Monteleone I; Sarra M; Pallone F; Monteleone G Curr Mol Med; 2012 Jun; 12(5):592-7. PubMed ID: 22515978 [TBL] [Abstract][Full Text] [Related]
30. Controversial Contribution of Th17/IL-17 Toward the Immune Response in Intestinal Fibrosis. Latella G; Viscido A Dig Dis Sci; 2020 May; 65(5):1299-1306. PubMed ID: 32124197 [TBL] [Abstract][Full Text] [Related]
31. Immunopathogenesis of inflammatory bowel diseases: functional role of T cells and T cell homing. Zundler S; Neurath MF Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S19-28. PubMed ID: 26458165 [TBL] [Abstract][Full Text] [Related]
32. Synergy of IL-23 and Th17 cytokines: new light on inflammatory bowel disease. Shen W; Durum SK Neurochem Res; 2010 Jun; 35(6):940-6. PubMed ID: 19915978 [TBL] [Abstract][Full Text] [Related]
33. High salt diet stimulates gut Th17 response and exacerbates TNBS-induced colitis in mice. Wei Y; Lu C; Chen J; Cui G; Wang L; Yu T; Yang Y; Wu W; Ding Y; Li L; Uede T; Chen Z; Diao H Oncotarget; 2017 Jan; 8(1):70-82. PubMed ID: 27926535 [TBL] [Abstract][Full Text] [Related]
34. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Tillack C; Ehmann LM; Friedrich M; Laubender RP; Papay P; Vogelsang H; Stallhofer J; Beigel F; Bedynek A; Wetzke M; Maier H; Koburger M; Wagner J; Glas J; Diegelmann J; Koglin S; Dombrowski Y; Schauber J; Wollenberg A; Brand S Gut; 2014 Apr; 63(4):567-77. PubMed ID: 23468464 [TBL] [Abstract][Full Text] [Related]
35. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells. Sasaoka T; Ito M; Yamashita J; Nakajima K; Tanaka I; Narita M; Hara Y; Hada K; Takahashi M; Ohno Y; Matsuo T; Kaneshiro Y; Tanaka H; Kaneko K Am J Physiol Gastrointest Liver Physiol; 2011 Apr; 300(4):G568-76. PubMed ID: 21193526 [TBL] [Abstract][Full Text] [Related]
36. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease? Zhang Z; Hinrichs DJ; Lu H; Chen H; Zhong W; Kolls JK Int Immunopharmacol; 2007 Apr; 7(4):409-16. PubMed ID: 17321463 [TBL] [Abstract][Full Text] [Related]
37. Intestinal neuroendocrine cells and goblet cells are mediators of IL-17A-amplified epithelial IL-17C production in human inflammatory bowel disease. Friedrich M; Diegelmann J; Schauber J; Auernhammer CJ; Brand S Mucosal Immunol; 2015 Jul; 8(4):943-58. PubMed ID: 25492478 [TBL] [Abstract][Full Text] [Related]
38. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Olsen T; Rismo R; Cui G; Goll R; Christiansen I; Florholmen J Cytokine; 2011 Dec; 56(3):633-40. PubMed ID: 21945121 [TBL] [Abstract][Full Text] [Related]
39. IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease. Abraham C; Cho JH Annu Rev Med; 2009; 60():97-110. PubMed ID: 18976050 [TBL] [Abstract][Full Text] [Related]
40. Protective and aggravating effects of Nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factors. Bauer C; Duewell P; Lehr HA; Endres S; Schnurr M Dig Dis; 2012; 30 Suppl 1():82-90. PubMed ID: 23075874 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]